TScan Therapeutics (NASDAQ:TCRX) Stock Rating Reaffirmed by Wedbush

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a report released on Wednesday, RTT News reports. They currently have a $10.00 price target on the stock. Wedbush’s price target would indicate a potential upside of 47.71% from the company’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a report on Thursday, March 7th.

TScan Therapeutics Stock Performance

NASDAQ TCRX traded down $0.36 during mid-day trading on Wednesday, reaching $6.77. 1,503,910 shares of the stock were exchanged, compared to its average volume of 183,401. The business’s 50 day moving average is $7.00 and its 200-day moving average is $5.62. TScan Therapeutics has a 1 year low of $1.62 and a 1 year high of $9.00. The company has a market capitalization of $324.15 million, a P/E ratio of -3.64 and a beta of 0.90. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.51 and a current ratio of 6.51.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. The firm had revenue of $7.21 million for the quarter, compared to analyst estimates of $2.94 million. TScan Therapeutics had a negative net margin of 423.86% and a negative return on equity of 60.65%. On average, equities research analysts forecast that TScan Therapeutics will post -1.04 EPS for the current fiscal year.

Hedge Funds Weigh In On TScan Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Stifel Financial Corp raised its stake in shares of TScan Therapeutics by 3.0% in the 4th quarter. Stifel Financial Corp now owns 120,400 shares of the company’s stock valued at $702,000 after acquiring an additional 3,500 shares during the period. Pale Fire Capital SE increased its position in shares of TScan Therapeutics by 30.2% in the 4th quarter. Pale Fire Capital SE now owns 21,573 shares of the company’s stock valued at $126,000 after purchasing an additional 4,998 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of TScan Therapeutics in the 2nd quarter valued at approximately $32,000. State Street Corp increased its position in shares of TScan Therapeutics by 79.1% in the 1st quarter. State Street Corp now owns 24,000 shares of the company’s stock valued at $50,000 after purchasing an additional 10,600 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of TScan Therapeutics in the 1st quarter valued at approximately $37,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.